<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurochem Res</journal-id><journal-id journal-id-type="iso-abbrev">Neurochem Res</journal-id><journal-title-group><journal-title>Neurochemical Research</journal-title></journal-title-group><issn pub-type="ppub">0364-3190</issn><issn pub-type="epub">1573-6903</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39641810</article-id><article-id pub-id-type="pmc">PMC11624226</article-id>
<article-id pub-id-type="publisher-id">4292</article-id><article-id pub-id-type="doi">10.1007/s11064-024-04292-9</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Exploring New and Promising Genetic Biomarkers for Evaluating Traumatic Brain Injuries: A Case-Control Study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Rabou</surname><given-names>Yasmin Kamal Abd</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zayed</surname><given-names>Abeer Ahmed</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7934-5030</contrib-id><name><surname>Fahim</surname><given-names>Sally A.</given-names></name><address><email>sallyatef@hotmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Abdelgwad</surname><given-names>Marwa</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Fiki</surname><given-names>Ahmed El</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Fayed</surname><given-names>Nermin Nabil</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03q21mh05</institution-id><institution-id institution-id-type="GRID">grid.7776.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0639 9286</institution-id><institution>Department of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, </institution><institution>Cairo University, </institution></institution-wrap>Kasr Alainy Street, Cairo, 11562 Egypt </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.517528.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 6020 2309</institution-id><institution>Department of Biochemistry, School of Pharmacy, </institution><institution>New Giza University (NGU), </institution></institution-wrap>New Giza, Km 22 Cairo- Alexandria Desert Road, P.O. Box 12577, Giza, Egypt </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03q21mh05</institution-id><institution-id institution-id-type="GRID">grid.7776.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0639 9286</institution-id><institution>Department of Biochemistry, Faculty of Medicine, </institution><institution>Cairo University, </institution></institution-wrap>Kasr Alainy Street, Cairo, 11562 Egypt </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03q21mh05</institution-id><institution-id institution-id-type="GRID">grid.7776.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0639 9286</institution-id><institution>Department of Neurosurgery, Faculty of Medicine, </institution><institution>Cairo University, </institution></institution-wrap>Kasr Alainy Street, Cairo, 11562 Egypt </aff></contrib-group><pub-date pub-type="epub"><day>6</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>6</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>50</volume><issue>1</issue><elocation-id>48</elocation-id><history><date date-type="received"><day>9</day><month>8</month><year>2024</year></date><date date-type="rev-recd"><day>9</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>15</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Traumatic brain injury (TBI) is a common cause of morbidity and death in all age groups, with an estimated 50&#x000a0;million people having brain injury due to trauma each year. Accurate blood-based biomarkers are needed to assist with diagnosis of patients across the spectrum of time and severity. Our objectives were to explore the diagnostic precision of time- and severity- related four blood-based biomarkers: AKT3, GSK-3&#x003b2;, hsa-miR-16-5p, and MALAT-1 for TBI for the purpose of diagnosis, prognosis, and follow-up. 40 samples were recruited as the following: 30 TBI patients and 10 healthy volunteers as controls with matched age and sex. They were divided according to the Glasgow Coma Scale into mild (mTBI), moderate (modTBI), and severe(sTBI) TBI. Blood samples were withdrawn at entry, and after 5 and 30 days, RT-PCR was used for measuring the expression level. The results showed upregulated expression levels of AKT3, hsa-miR-16-5p and significantly downregulated expression levels of GSK-3&#x003b2; in TBI patients compared to controls at all timings measured. mTBI patients showed a higher expression level of hsa-miR-16-5p compared with modTBI, and sTBI patients. MALAT-1 level showed a significant increase in severe cases only. We concluded that AKT3, hsa-miR-16-5p, and GSK-3&#x003b2; are excellent diagnostic biomarkers in TBI patients at initial assessment, as well as at 5 and 30 days following the injury. Moreover, MALAT-1 had good diagnostic value in sTBI patients, and its prognostic value extends to 30 days. GSK-3&#x003b2; was an excellent biomarker for detecting mTBI.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>hsa-miR-16-5p</kwd><kwd>MALAT 1</kwd><kwd>GSK-3&#x003b2;</kwd><kwd>AKT3</kwd><kwd>TBI</kwd></kwd-group><funding-group><award-group><funding-source><institution>New Giza University</institution></funding-source></award-group><open-access><p>Open access funding provided by The Science, Technology &#x00026; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">Traumatic brain injury (TBI), often referred to as the &#x0201c;silent epidemic&#x0201d;, refers to the functional impairment of the brain caused by external forces [<xref ref-type="bibr" rid="CR1">1</xref>]. TBI is represents the most significant contributor to death and disability globally among all trauma-related injuries, with an estimated 27.16&#x000a0;million new cases and 48.99&#x000a0;million existing cases [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par3">The Glasgow Coma Scale (GCS), a longstanding clinical tool dependent on physical examination findings, is utilized to measure the severity of TBI [<xref ref-type="bibr" rid="CR5">5</xref>]. Predicting the outcome of patients after a TBI lacks precision when relying exclusively on clinical signs and radiographic observations. Individuals with apparently similar injuries often experience markedly different outcomes [<xref ref-type="bibr" rid="CR6">6</xref>]. TBI can give rise to various neurological and behavioral disorders, making it challenging to evaluate prognosis and monitor associated injuries arising from secondary inflammatory processes [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par4">Many of the studied biomarkers demonstrate low sensitivity, particularly in cases of Mild Traumatic Brain Injury (mTBI) where individuals lack visible intracranial lesions and exhibit minimal observable symptoms. Additionally, the timing of the injury can have significant relevance in forensic investigations as it can influence the stage of injury progression and healing processes. Moreover, the biomarkers associated with inflammation, tissue damage, and recovery pathways vary depending on the time elapsed since the injury occurred [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par5">Non-coding RNAs (ncRNAs) have emerged as key regulators in various biological processes, as evidenced by multiple research studies preventing neuronal damage resulting from brain injuries, potentially leading to better outcomes for individuals with TBI [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. Moreover, in recent decades, there has been substantial progress in the advancement of high-throughput RNA sequencing and bioinformatics and tools to study how genes are activated or inhibited, showing significant growth in this field [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par6">MicroRNAs (miRNAs) are types of regulatory non-coding RNAs. These are important in managing post-transcriptional gene expression across various species by aiming multiple mRNAs through sequence complementarity and typically suppressing these target RNAs [<xref ref-type="bibr" rid="CR17">17</xref>]. Dysregulation of miRNAs has a role in neurodevelopment and the proper functioning of the brain by regulating vital cellular processes related to both neuronal injury and their subsequent repair mechanisms [<xref ref-type="bibr" rid="CR18">18</xref>]. Lower levels of hsa-miR-16-5p have been attributed to faster fracture healing in people with TBI. This effect is achieved by stimulating the growth of osteoblasts and suppressing apoptosis [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par7">Long non-coding RNAs (LncRNAs) represent a relatively new class of RNA molecules, typically exceeding 200 nucleotides in length [<xref ref-type="bibr" rid="CR10">10</xref>]. Among these LncRNAs, MALAT-1 is noteworthy for its influence on endothelial cell function and the growth of blood vessels [<xref ref-type="bibr" rid="CR20">20</xref>]. Increased expression of MALAT-1 has been linked to improvements in brain edema in cases of TBI [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par8">Glycogen Synthase Kinase 3&#x003b2; (GSK-3&#x003b2;) was known as a controller of glycogen metabolism and was linked to a diverse array of cellular processes, encompassing protein synthesis, cell growth, cellular differentiation, cell motility, and the control of apoptosis. It is worth noting that neuronal cell derangement especially apoptosis has been linked to GSK-3&#x003b2; activity [<xref ref-type="bibr" rid="CR22">22</xref>]. It was found that inhibition of GSK-3&#x003b2; prevented cognitive deficits after TBI [<xref ref-type="bibr" rid="CR23">23</xref>]. Akt1, Akt2, and Akt3 are three forms of the AKT family, known as protein kinase b. Akt3 is the predominant form of AKT found in the brain, and it has been reported that the phosphorylation of Akt is also implicated in the signaling pathways that influence cell survival following TBI [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par9">Therefore, the aim of our study is to detect the levels of MALAT-1, hsa-miR16-5p, GSK-3&#x003b2;, and AKT3 in the plasma of mild, moderate, and severe TBI (mTBI, ModTBI, sTBI) patients after 5 and 30 days of trauma and compare them to the baseline at injury day. Therefore, exploring their potential utility as biomarkers for diagnosing, prognosing, and monitoring TBI patients, in addition to their significant relevance in forensic investigation. Moreover, the target genes and functional analysis has been identified using bioinformatics.</p></sec><sec id="Sec2"><title>Subjects and Methods</title><sec id="Sec3"><title>Bioinformatics and Rationale of Biomarkers Choice</title><p id="Par10">GSK-3&#x003b2; and AKT3, relevant protein-coding genes, were selected from the Gene Atlas (<ext-link ext-link-type="uri" xlink:href="http://genatlas.medecine.univ-paris5.fr/">http://genatlas.medecine.univ-paris5.fr/</ext-link>) as they are well expressed in the TBI patients [<xref ref-type="bibr" rid="CR25">25</xref>] and were involved in cognitive deficits and cell survival after TBI [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Then, hsa-miR-16-5p was identified by TargetScan (<ext-link ext-link-type="uri" xlink:href="https://www.targetscan.org/vert_80/">https://www.targetscan.org/vert_80/</ext-link>) [<xref ref-type="bibr" rid="CR26">26</xref>], miRDB (<ext-link ext-link-type="uri" xlink:href="https://mirdb.org/">https://mirdb.org/</ext-link>) [<xref ref-type="bibr" rid="CR27">27</xref>], and RNAv22 (<ext-link ext-link-type="uri" xlink:href="https://cm.jefferson.edu/rna22/Interactive/">https://cm.jefferson.edu/rna22/Interactive/</ext-link>) [<xref ref-type="bibr" rid="CR28">28</xref>] targeting both GSK-3&#x003b2; and AKT3, in addition to its role in neurodevelopment, the proper functioning and repair mechanisms of the brain following TBI [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Finally, the lncRNA, MALAT-1 is determined by accessing the Diana database (<ext-link ext-link-type="uri" xlink:href="http://carolina.imis.athenainnovation.gr/diana_tools/web/index.php?r=tarbasev8%2Findex">http://carolina.imis.athenainnovation.gr/diana_tools/web/index.php?r=tarbasev8%2Findex</ext-link>) [<xref ref-type="bibr" rid="CR29">29</xref>] and confirming its role in both sponging hsa-miR-16-5p and improving brain edema in cases of TBI [<xref ref-type="bibr" rid="CR21">21</xref>]. Cytoscape software (V 3.10.1) was then used to form networks illustrating the miRNA target genes [<xref ref-type="bibr" rid="CR30">30</xref>]. DAVID database (<ext-link ext-link-type="uri" xlink:href="https://david.ncifcrf.gov/summary.jsp">https://david.ncifcrf.gov/summary.jsp</ext-link>) [<xref ref-type="bibr" rid="CR31">31</xref>] was used for gene ontology to categorize what they do, where they work in the cell, and how they contribute to cell function., in addition to functional enrichment analysis including the KEGG pathway.</p></sec><sec id="Sec4"><title>Study Design</title><p id="Par11">This case-control study comprises 30 TBI cases and 10 healthy controls, TBI cases were recruited from the neurosurgery, emergency departments, and outpatient clinic at Kasr Alainy Hospital, Cairo University, between July 2022 and January 2023 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). This study was conducted with ethical approval at Kasr Alainy Hospital (MD-109-2021) and conducted according to the ethical principles outlined in the Declaration of Helsinki. All participants provided written informed consent. Participants with TBI either provided written informed consent or, in cases where they were incapable or unconscious of providing consent, approval was sought from their legal representative. Patients who entered the hospital without caregivers or guardians are excluded from the study.</p><p id="Par12">TBI cases were differentiated according to GCS, into mTBI (13&#x02013;15) scores, modTBI (9&#x02013;12) scores, or sTBI (3&#x02013;8) scores [<xref ref-type="bibr" rid="CR32">32</xref>]. Additionally, 10 healthy controls matched for age- and sex-seeking routine health check-ups were recruited from the same hospital. Every patient in our research received a CT scan within 24&#x000a0;h upon arrival at the emergency department.</p><p id="Par13">The inclusion criteria for patients included being adults between the ages of 18 and 45, irrespective of gender, and having experienced recent head trauma. Exclusion criteria encompassed pregnant or nursing women, individuals with diabetes, hypertension, or other significant cardiovascular diseases, and those with debilitating neurological conditions of pathological origin, concurrent spinal cord injuries, or injuries resulting from substance abuse or alcoholism.</p><p id="Par14">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Fow chart of participants</p></caption><graphic xlink:href="11064_2024_4292_Fig1_HTML" id="d33e404"/></fig>
</p></sec><sec id="Sec5"><title>Sample Collection and Biochemical Analysis</title><p id="Par15">Five milliliters of blood were collected from both cases and control groups in EDTA tubes within 24&#x000a0;h of admission then sent to the laboratory within 30&#x000a0;min of collection. The blood was then centrifuged at 4,000 xg for 10&#x000a0;min to isolate the plasma and immediately frozen at &#x02212;&#x02009;80<sup>o</sup>C for subsequent RNA extraction. To minimize bias, group allocation (intervention vs. control) and outcome assessment were blinded.</p><sec id="Sec6"><title>RNA Extraction</title><p id="Par16">Total RNA was extracted from the plasma samples using a commercially available kit using a commercially available kit (miRNeasy, Qiagen) designed specifically for extracting small RNAs. The concentration and purity of the extracted RNA were quantified using a NanoDrop spectrophotometer. <sup>&#x000ae;</sup> (ND)-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA.</p></sec><sec id="Sec7"><title>Reverse Transcription (RT) and real-time Quantitative PCR (qPCR)</title><p id="Par17">
<list list-type="bullet"><list-item><p id="Par18"><bold>LncRNA and Gene Expression</bold>: ELK Green One-Step qRT-PCR Super Mix kit (Cat. No. Equations&#x000a0;007-02) was used to quantify the expression of the lncRNA; MALAT-1, and GSK-3&#x003b2; and AKT3 genes. This kit utilizes a three-step cycling protocol:</p><p id="Par19">
<list list-type="bullet"><list-item><p id="Par20">&#x025cb; Reverse transcription: 1 cycle at 50&#x000a0;&#x000b0;C for 15&#x000a0;min.</p></list-item><list-item><p id="Par21">&#x025cb; Predenaturation: 1 cycle at 95&#x000a0;&#x000b0;C for 2&#x000a0;min.</p></list-item><list-item><p id="Par22">&#x025cb; Amplification: 40 cycles of:</p><p id="Par23">
<list list-type="bullet"><list-item><p id="Par24">Denaturation: 95&#x000a0;&#x000b0;C for 10&#x000a0;s.</p></list-item><list-item><p id="Par25">Annealing: 50&#x02013;60&#x000a0;&#x000b0;C for 30&#x000a0;s.</p></list-item><list-item><p id="Par26">Extension: 72&#x000a0;&#x000b0;C for 30&#x000a0;s.</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p id="Par27"><bold>MicroRNA Expression</bold>: For microRNA-16-5p (hsa-miR-16-5p) quantification, a separate miRCURY LNA RT Kit (Qiagen, Cat. No. 339345) was used for reverse transcription. Two microliters (2 &#x000b5;L) of extracted RNA were reverse transcribed into cDNA in a final reaction volume of 10 &#x000b5;L. The RT reaction consisted of incubation at 37&#x000a0;&#x000b0;C for 60&#x000a0;min, followed by enzyme inactivation at 85&#x000a0;&#x000b0;C for 5&#x000a0;s.</p></list-item><list-item><p id="Par28"><bold>Real-Time PCR Setup</bold>: For both lncRNA/gene and miRNA analysis, a 10 &#x000b5;L reaction volume per well was prepared. The real-time PCR program used the following steps:</p><p id="Par29">
<list list-type="bullet"><list-item><p id="Par30">&#x025cb; Initial activation: 95&#x000a0;&#x000b0;C for 2&#x000a0;min.</p></list-item><list-item><p id="Par31">&#x025cb; Cycling:</p><p id="Par32">
<list list-type="bullet"><list-item><p id="Par33">Denaturation: 95&#x000a0;&#x000b0;C for 10&#x000a0;s.</p></list-item><list-item><p id="Par34">Combined annealing and extension: 56&#x000a0;&#x000b0;C for 60&#x000a0;s (40 cycles).</p></list-item></list>
</p></list-item></list>
</p></list-item></list>
</p><p id="Par35">Gene expression levels of MALAT-1, GSK-3&#x003b2;, and AKT3 were measured using quantitative reverse transcription PCR (RT-qPCR) on an Applied Biosystems StepOne&#x02122; instrument (version 3.1, USA). GAPDH was used as a reference gene to normalize the expression of these genes. For the hsa-miR-16-5p, U6 was used as the reference gene. The 2<sup>-&#x00394;&#x00394;Ct</sup> method was employed to analyze the RT-qPCR results.</p><p id="Par36">All Primers are listed in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and their specificity was checked using primer Blast (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/tools/primer-blast/">https://www.ncbi.nlm.nih.gov/tools/primer-blast/</ext-link>). All the primers utilized demonstrated 100% efficiency. To assess the efficiency, a 10-fold dilution of our target was prepared, and a regular real-time PCR run was conducted. The Ct (threshold cycle) values obtained from the qRT-PCR experiment were plotted on the y-axis (logarithmic scale) against the corresponding known concentrations of the starting material (e.g., RNA) on the x-axis using GraphPad software, A linear regression analysis was performed on the plotted data points to generate a best-fit trend line. The slope of the generated trend line was then calculated. Finally, the PCR efficiency (E) was determined using the equation: E = -1 +10^(-1/slope).</p><p id="Par37">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>List of primers</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Primer</th><th align="left">Accession number</th></tr></thead><tbody><tr><td align="left">hsa-miR-16-5p</td><td align="left"><p>F-3&#x02019;TGGGGTAGCAGCACGTAAA&#x02019;5</p><p>R-3&#x02019;CTCAACTGGTGTCGTGGAGTC&#x02019;5</p></td><td align="left">MIMAT0000069</td></tr><tr><td align="left">MALAT-1</td><td align="left"><p>F-3&#x02019;GAATTGCGTCATTTAAAGCCTA&#x02019;5</p><p>R-3&#x02019;GTT GTTTCATCCTACCACTCCCAATTAAT&#x02019;5</p></td><td align="left">NR_145459.1</td></tr><tr><td align="left">GSK3-&#x003b2;</td><td align="left"><p>F-3&#x02019;GGAACTCCAACAAGGGAGCA&#x02019;5</p><p>R-3&#x02019;TTCGGGGTCGGAAGACCTTA&#x02019;5</p></td><td align="left">NM_001146156.2</td></tr><tr><td align="left">Akt3</td><td align="left"><p>F-3&#x02019;TGGACCACTGTTATAGAGAGAACATTT&#x02019;5</p><p>R-3&#x02019;TGGATAGCTTCCGTCCACTC&#x02019;5</p></td><td align="left">NM_001206729.2</td></tr><tr><td align="left">GAPDH</td><td align="left"><p>F-3&#x02019;ACAGTCAGCCGCATCTTCTT&#x02019;5</p><p>R-3&#x02019;GACAAGCTTC CCGTTCTCAG&#x02019;5</p></td><td align="left">NM_001357943.2</td></tr><tr><td align="left">U6</td><td align="left"><p>F-3&#x02019;CTCGCTTCGGCAGCACA&#x02019;5</p><p>R-3&#x02019;AACGCTTCACGAATTTGCGT&#x02019;5</p></td><td align="left">NR_104084.1</td></tr></tbody></table><table-wrap-foot><p>MALAT-1: metastasis-associated lung adenocarcinoma transcript 1, GSK-3&#x003b2;: Glycogen synthase kinase B, Akt3: AKT serine/threonine kinase 3,GAPDH: Glyceraldehyde-3-phosphate dehydrogenase, U6:urokinase</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec8"><title>Statistical Analysis</title><p id="Par38">The data underwent encoding and entry into the statistical software program called SPSS V28 (IBM Corp. in Armonk, NY, USA). For numerical data, data was represented using mean and standard deviation. Categorical data was represented as number and percent. unpaired t-tests or analysis of variance (ANOVA) were employed to compare between groups, for normally distributed quantitative variables. Conversely, non-parametric tests such as the Kruskal-Wallis and Mann-Whitney tests were utilized for quantitative variables that did not follow a normal distribution [<xref ref-type="bibr" rid="CR33">33</xref>], For categorical data analysis, the Chi-squared (&#x003c7;2) test was conducted, and in cases where the expected frequency was less than five, the Fisher-exact test was utilized [<xref ref-type="bibr" rid="CR33">33</xref>]. The correlation between quantitative variables was assessed through the computation of Spearman&#x02019;s correlation coefficient [<xref ref-type="bibr" rid="CR34">34</xref>]. To identify the optimal cutoff values for significant markers in detecting cases, ROC curves were created.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Demographic and Medicolegal data of TBI Patients</title><p id="Par39">Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> shows the characteristics of the study participants. Patients were older than 18 years, Age and gender distribution were comparable between the groups (no significant differences (<italic>P</italic>&#x02009;&#x0003e;&#x02009;0.05). The patients were subdivided based on severity: mTBI, modTBI, and sTBI according to their GCS scores with a median of 15,12, and 6, respectively. 100% of the severely injured patients had hemorrhage of which 40% died. homicidal is equal to abuse and deliberate assault and violence as hitting by a brick or a stick intentionally, deliberate throwing the case on stairs in quarrel or gun shot.</p><p id="Par40">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Demographic and injury characteristics of study participants</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="3">TBI (<italic>n</italic>&#x02009;=&#x02009;30)</th><th align="left" rowspan="2"><italic>P</italic>-Value</th></tr><tr><th align="left">Mild<break/>(<italic>n</italic>&#x02009;=&#x02009;10)</th><th align="left">Moderate<break/>(<italic>n</italic>&#x02009;=&#x02009;10)</th><th align="left">Severe<break/>(<italic>n</italic>&#x02009;=&#x02009;10)</th></tr></thead><tbody><tr><td align="left">
<bold>Age</bold>
</td><td align="left">30.1&#x02009;&#x000b1;&#x02009;11.4</td><td align="left">31&#x02009;&#x000b1;&#x02009;8.9</td><td align="left">29.9&#x02009;&#x000b1;&#x02009;8.2</td><td align="left">0.68</td></tr><tr><td align="left" colspan="5">
<bold>Sex</bold>
</td></tr><tr><td align="left"><p>Male</p><p>Female</p></td><td align="left"><p>9 (90%)</p><p>1 (10%)</p></td><td align="left"><p>9 (90%)</p><p>1 (10%)</p></td><td align="left"><p>9 (90%)</p><p>1 (10%)</p></td><td align="left">0.19</td></tr><tr><td align="left" colspan="5">
<bold>Occupation</bold>
</td></tr><tr><td align="left"><p>Manual work</p><p>Mental work</p><p>Student</p><p>None</p></td><td align="left"><p>7 (70%)</p><p>0 (0%)</p><p>1 (10%)</p><p>2(20%)</p></td><td align="left"><p>5 (50%)</p><p>3 (30%)</p><p>0 (0%)</p><p>2 (20%)</p></td><td align="left"><p>6 (60%)</p><p>1 (10%)</p><p>2 (20%)</p><p>1 (10%)</p></td><td align="left">0.39</td></tr><tr><td align="left" colspan="5">
<bold>Residence</bold>
</td></tr><tr><td align="left"><p>Urban</p><p>Rural</p></td><td align="left"><p>5 (50%)</p><p>5 (50%)</p></td><td align="left"><p>5 (50%)</p><p>5 (50%)</p></td><td align="left"><p>7 (70%)</p><p>3 (30%)</p></td><td align="left">0.58</td></tr><tr><td align="left" colspan="5">
<bold>Mechanism of Injury</bold>
</td></tr><tr><td align="left"><p>Road traffic injury</p><p>Fall from height</p><p>Violence</p><p>Work accident</p><p>Other</p></td><td align="left"><p>2 (20%)</p><p>0 (0%)</p><p>5 (50%)</p><p>3 (30%)</p><p>0 (0%)</p></td><td align="left"><p>3 (30%)</p><p>2 (20%)</p><p>4 (40%)</p><p>0 (0%)</p><p>1 (10%)</p></td><td align="left"><p>7 (70%)</p><p>1 (10%)</p><p>0 (0%)</p><p>0 (0%)</p><p>2 (20%)</p></td><td align="left">0.02*</td></tr><tr><td align="left" colspan="5">
<bold>Manner of injury</bold>
</td></tr><tr><td align="left"><p>Accidental</p><p>Homicidal</p></td><td align="left"><p>5 (50%)</p><p>5 (50%)</p></td><td align="left"><p>6 (60%)</p><p>4 (40%)</p></td><td align="left"><p>8 (80%)</p><p>2 (20%)</p></td><td align="left">0.36</td></tr><tr><td align="left">
<bold>GCS</bold>
</td><td align="left">15 (13&#x02013;15)</td><td align="left">12 (9&#x02013;12)</td><td align="left">6 (3&#x02013;8)</td><td align="left">&#x0003c;&#x02009;0.0001****</td></tr><tr><td align="left" colspan="5">
<bold>CT changes</bold>
</td></tr><tr><td align="left"><p>Contusion</p><p>Hemorrhage</p><p>&#x02003;Extradural</p><p>&#x02003;Subdural</p><p>&#x02003;Intracerebral</p><p>&#x02003;Subarachnoid</p><p>Combined</p><p>DAI</p></td><td align="left"><p>5 (50%)</p><p>5 (50%)</p><p>4</p><p>0</p><p>0</p><p>1</p><p>0</p><p>0 (0%)</p></td><td align="left"><p>0 (0%)</p><p>8 (80%)</p><p>3</p><p>2</p><p>2</p><p>1</p><p>2 (20%)</p><p>0 (0%)</p></td><td align="left"><p>0 (0%)</p><p>3 (30%)</p><p>1</p><p>0</p><p>1</p><p>1</p><p>4 (40%)</p><p>3 (30%)</p></td><td align="left">&#x0003c;&#x02009;0.001***</td></tr><tr><td align="left" colspan="5">
<bold>Outcome</bold>
</td></tr><tr><td align="left"><p>Recovered</p><p>Complicated</p><p>Permanent infirmity</p><p>Died</p></td><td align="left"><p>10 (100%)</p><p>0 (0%)</p><p>0 (0%)</p><p>0 (0%)</p></td><td align="left"><p>7 (70%)</p><p>1 (10%)</p><p>2(20%)</p><p>0 (0%)</p></td><td align="left"><p>0 (0%)</p><p>6 (60%)</p><p>0 (0%)</p><p>4 (40%)</p></td><td align="left">&#x0003c;&#x02009;0.0001****</td></tr><tr><td align="left" colspan="5">
<bold>Headache</bold>
</td></tr><tr><td align="left"><p>Yes</p><p>No</p></td><td align="left"><p>9 (90%)</p><p>1 (10%)</p></td><td align="left"><p>9 (90%)</p><p>1 (10%)</p></td><td align="left">NA</td><td align="left">1</td></tr><tr><td align="left" colspan="5">
<bold>Vertigo</bold>
</td></tr><tr><td align="left"><p>Yes</p><p>No</p></td><td align="left"><p>2 (20%)</p><p>8 (80%)</p></td><td align="left"><p>5 (50%)</p><p>5 (50%)</p></td><td align="left">NA</td><td align="left">0.16</td></tr><tr><td align="left" colspan="5">
<bold>Insomnia</bold>
</td></tr><tr><td align="left"><p>Yes</p><p>No</p></td><td align="left"><p>2 (20%)</p><p>8 (80%)</p></td><td align="left"><p>2 (20%)</p><p>8 (80%)</p></td><td align="left">NA</td><td align="left">1</td></tr><tr><td align="left" colspan="5">
<bold>Cognitive</bold>
</td></tr><tr><td align="left"><p>Yes</p><p>No</p></td><td align="left"><p>1 (10%)</p><p>9 (90%)</p></td><td align="left"><p>4 (40%)</p><p>6 (60%)</p></td><td align="left">NA</td><td align="left">0.12</td></tr><tr><td align="left">
<bold>Time od injury to admission</bold>
</td><td align="left">6.7&#x02009;&#x000b1;&#x02009;2.04</td><td align="left">5.15&#x02009;&#x000b1;&#x02009;2.12</td><td align="left">4.8&#x02009;&#x000b1;&#x02009;2.33</td><td align="left">0.806</td></tr></tbody></table><table-wrap-foot><p>* Significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, ** significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, *** significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, **** significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001. Data are expressed as mean&#x02009;&#x000b1;&#x02009;SD, or n (%). All Data was analyzed using Chi square (X<sup>2</sup>) test, while age was analyzed using one-way ANOVA and Tukey&#x02019;s multiple comparisons test. GCS: Glasgow coma scale, DAI: diffuse axonal injury</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec11"><title>AKT3 and GSK-&#x003b2;3 gene Expression Levels Between Different TBI Groups and at Different Times (0, 5, and 30 days)</title><p id="Par41">The results showed a significant increase AKT3 levels in TBI patients compared to the control at 0, 5, and 30 days (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A). Moreover, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B shows that AKT3 expression level was significantly increased in mTBI, modTBI, and sTBI cases in comparison to the control at P-value&#x02009;&#x0003c;&#x02009;0.001, while no significant change was detected according to the severity of the TBI. When comparing the AKT3 levels among the three time points, it didn&#x02019;t change in patients with mTBI, while its level showed a significant decrease in modTBI and sTBI patients after 5 and 30 days (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C) when compared to the baseline time. On the other hand, GSK-3&#x003b2; expression level decreased in TBI patients compared to the control at 0, 5, and 30 days. The decrease in GSK-3&#x003b2; expression level was gradual over time where its level decreased after 5 and 30 days compared to its level at day zero (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>D). GSK-3&#x003b2; level was significantly decreased in all TBI severity groups in comparison to the control (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>E). Moreover, GSK-&#x003b2;3 levels further decreased after 5 and 30 days in mTBI cases compared to T0, while their levels didn&#x02019;t significantly change after 5 and 30 days in modTBI and sTBI patients (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>F).</p><p id="Par42">
<fig id="Fig2"><label>Fig. 2</label><caption><p>The gene expression level of AKT3 and GSK-&#x003b2;3 in all TBI patients at 0, 5, and 30 days (<bold>A</bold> &#x00026; <bold>D</bold>), in mTBI, modTBI, and sTBI patients (<bold>B</bold> &#x00026; <bold>E</bold>), and in mTBI, modTBI, and sTBI patients at 0, 5, and 30 days following the trauma (<bold>C</bold> &#x00026; <bold>F</bold>), data are shown as log10RQ. Error bars show the standard deviation. A p-value&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant, * significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, ** significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, *** significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001</p></caption><graphic xlink:href="11064_2024_4292_Fig2_HTML" id="d33e1064"/></fig>
</p></sec><sec id="Sec12"><title>The Expression Level of the miRNA; hsa-miR-16-5p and the lncRNA; MALAT-1 of Different TBI Severity Patients at Different Timings</title><p id="Par43">MALAT-1 level showed a significant increase in severe cases in comparison to the control, mTBI and modTBI, cases (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.0001), while its level did not significantly change in individuals with mTBI or modTBI compared to a healthy control group (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B). When comparing the MALAT-1 levels among the three time points, the change wasn&#x02019;t significant even after 30 days in patients with mTBI and modTBI, while its level showed a significant increase after 30 days in sTBI patients (<italic>P</italic> &#x0003c; 0.01, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>C) when compared to the baseline time. The results showed a significant increase in hsa-miR-16-p levels in TBI patients compared to the control group at 0, 5, and 30 days (<italic>P</italic> &#x0003c; 0.0001) as shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>D. hsa-miR-16-5p level increased in all TBI cases compared to the control (<italic>P</italic> &#x0003c; 0.0001), interestingly, mTBI patients showed a higher expression level compared with modTBI, and sTBI patients with <italic>P</italic> &#x0003c; 0.01 and &#x0003c; 0.05, respectively (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>E). Moreover, after 30 days following trauma, mTBI patients, in contrast to modTBI, showed an increase in the level of hsa-miR-16-5p compared to the baseline time (<italic>P</italic> &#x0003c; 0.0001, Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>F).</p><p id="Par44">
<fig id="Fig3"><label>Fig. 3</label><caption><p>MALAT-1 and hsa-miR-16-5p expression level in all TBI patients at 0, 5, and 30 days (<bold>A</bold> &#x00026; <bold>D</bold>), in mTBI, modTBI, and sTBI patients (<bold>B</bold> &#x00026; <bold>E</bold>), in mTBI, modTBI, and sTBI patients at 0, 5, and 30 days following the trauma (<bold>C</bold> &#x00026; <bold>F</bold>). Data are represented as log<sub>10</sub>RQ. Error bars represent the standard deviation. A p-value&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant, <sup>*</sup> significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, <sup>**</sup> significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup>***</sup> significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, <sup>****</sup> significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001</p></caption><graphic xlink:href="11064_2024_4292_Fig3_HTML" id="d33e1155"/></fig>
</p></sec><sec id="Sec13"><title>Diagnostic Performance of the MALAT-1, hsa-miR-16-5p, GSK-3&#x003b2;, and AKT3</title><p id="Par45">ROC curve results indicated that AKT3, GSK-3&#x003b2;, and hsa-miR-16-5p were excellent diagnostic biomarkers for differentiation between TBI cases and control at time of admission and even after 5 and 30 days with area under the curve (AUC) exceeding 0.95 at all timings (<italic>P</italic> &#x0003c; 0.0001, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Furthermore, the levels of various biomarkers could distinguish between different severity outcomes of TBI based on the timing of assessment. Specifically, GSK-3&#x003b2; could differentiate between mild TBI and other cases at 0 time and after 5 days, whereas MALAT-1 after 30 days post-injury. On the other hand, MALAT-1 could discriminate between sTBI from mTBI and modTBI at 0 time (AUC=0.85, sensitivity=90% and specificity=70%, <italic>P</italic>=0.002) and after 5 (AUC=0.985, sensitivity=90 and specificity=95, <italic>P</italic>&#x0003c;0.0001) and 30 days of injury with AUC of 0.995, sensitivity and specificity equal 90% and 95%, respectively at <italic>P</italic>&#x0003c;0.0001.</p><p id="Par46">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>ROC curve analysis of MALAT-1, hsa-miR-16-5p, GSK-3&#x003b2;, and AKT3 stratified by time and severity</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Time (days)</th><th align="left">Biomarkers</th><th align="left">AUC</th><th align="left">95% CI</th><th align="left"><italic>P</italic>-Value</th><th align="left">Sensitivity (%)</th><th align="left">Specificity (%)</th></tr></thead><tbody><tr><td align="left" colspan="7">Control vs. all TBI patients</td></tr><tr><td align="left" rowspan="4">0</td><td align="left">AKT3</td><td align="left">
<bold>1</bold>
</td><td align="left">
<bold>1&#x02013;1</bold>
</td><td align="left">
<bold>&#x0003c;&#x02009;0.0001****</bold>
</td><td align="left">
<bold>100</bold>
</td><td align="left">
<bold>100</bold>
</td></tr><tr><td align="left">GSK-3&#x003b2;</td><td align="left">
<bold>1</bold>
</td><td align="left">
<bold>1&#x02013;1</bold>
</td><td align="left">
<bold>&#x0003c;&#x02009;0.0001****</bold>
</td><td align="left">
<bold>100</bold>
</td><td align="left">
<bold>100</bold>
</td></tr><tr><td align="left">MALAT-1</td><td align="left">0.65</td><td align="left">0.49&#x02013;0.815</td><td align="left">0.15</td><td align="left">56.7</td><td align="left">70</td></tr><tr><td align="left">hsa-miR-16-5p</td><td align="left">
<bold>1</bold>
</td><td align="left">
<bold>1&#x02013;1</bold>
</td><td align="left">
<bold>&#x0003c;&#x02009;0.0001****</bold>
</td><td align="left">
<bold>100</bold>
</td><td align="left">
<bold>100</bold>
</td></tr><tr><td align="left" rowspan="4">5</td><td align="left">AKT3</td><td align="left">
<bold>1</bold>
</td><td align="left">
<bold>1&#x02013;1</bold>
</td><td align="left">
<bold>&#x0003c;&#x02009;0.0001****</bold>
</td><td align="left">
<bold>100</bold>
</td><td align="left">
<bold>100</bold>
</td></tr><tr><td align="left">GSK-3&#x003b2;</td><td align="left">
<bold>1</bold>
</td><td align="left">
<bold>1&#x02013;1</bold>
</td><td align="left">
<bold>&#x0003c;&#x02009;0.0001****</bold>
</td><td align="left">
<bold>100</bold>
</td><td align="left">
<bold>100</bold>
</td></tr><tr><td align="left">MALAT-1</td><td align="left">0.78</td><td align="left">0.637&#x02013;0.923</td><td align="left">0.009**</td><td align="left">76</td><td align="left">70</td></tr><tr><td align="left">hsa-miR-16-5p</td><td align="left">
<bold>0.967</bold>
</td><td align="left">
<bold>0.92-1</bold>
</td><td align="left">
<bold>&#x0003c;&#x02009;0.0001****</bold>
</td><td align="left">
<bold>96</bold>
</td><td align="left">
<bold>100</bold>
</td></tr><tr><td align="left" rowspan="4">30</td><td align="left">AKT3</td><td align="left">
<bold>0.983</bold>
</td><td align="left">
<bold>0.948-1</bold>
</td><td align="left">
<bold>&#x0003c;&#x02009;0.0001****</bold>
</td><td align="left">
<bold>96.7</bold>
</td><td align="left">
<bold>100</bold>
</td></tr><tr><td align="left">GSK-3&#x003b2;</td><td align="left">
<bold>1</bold>
</td><td align="left">
<bold>1&#x02013;1</bold>
</td><td align="left">
<bold>&#x0003c;&#x02009;0.0001****</bold>
</td><td align="left">
<bold>100</bold>
</td><td align="left">
<bold>100</bold>
</td></tr><tr><td align="left">MALAT-1</td><td align="left">0.71</td><td align="left">0.551&#x02013;0.869</td><td align="left">0.049</td><td align="left">66.7</td><td align="left">70</td></tr><tr><td align="left">hsa-miR-16-5p</td><td align="left">
<bold>1</bold>
</td><td align="left">
<bold>1&#x02013;1</bold>
</td><td align="left">
<bold>&#x0003c;&#x02009;0.0001****</bold>
</td><td align="left">
<bold>100</bold>
</td><td align="left">
<bold>100</bold>
</td></tr><tr><td align="left" colspan="7">
<bold>mTBI vs. modTBI and sTBI</bold>
</td></tr><tr><td align="left" rowspan="4">0</td><td align="left">AKT3</td><td align="left">0.58</td><td align="left">0.34&#x02013;0.81</td><td align="left">0.48</td><td align="left">60</td><td align="left">70</td></tr><tr><td align="left">GSK-3&#x003b2;</td><td align="left">
<bold>0.94</bold>
</td><td align="left">
<bold>0.86-1</bold>
</td><td align="left">
<bold>&#x0003c;&#x02009;0.0001****</bold>
</td><td align="left">
<bold>80</bold>
</td><td align="left">
<bold>90</bold>
</td></tr><tr><td align="left">MALAT-1</td><td align="left">0.76</td><td align="left">0.54&#x02013;0.99</td><td align="left">0.02*</td><td align="left">75</td><td align="left">80</td></tr><tr><td align="left">hsa-miR-16-5p</td><td align="left">0.64</td><td align="left">0.44&#x02013;0.84</td><td align="left">0.22</td><td align="left">65</td><td align="left">60</td></tr><tr><td align="left" rowspan="4">5</td><td align="left">AKT3</td><td align="left">0.39</td><td align="left">0.135&#x02013;0.655</td><td align="left">0.35</td><td align="left">70</td><td align="left">40</td></tr><tr><td align="left">GSK-3&#x003b2;</td><td align="left">
<bold>0.8</bold>
</td><td align="left">
<bold>0.619&#x02013;0.981</bold>
</td><td align="left">
<bold>0.008**</bold>
</td><td align="left">
<bold>80</bold>
</td><td align="left">
<bold>80</bold>
</td></tr><tr><td align="left">MALAT-1</td><td align="left">0.78</td><td align="left">0.599&#x02013;0.9961</td><td align="left">0.01*</td><td align="left">85</td><td align="left">60</td></tr><tr><td align="left">hsa-miR-16-5p</td><td align="left">0.48</td><td align="left">0.24&#x02013;0.72</td><td align="left">0.89</td><td align="left">60</td><td align="left">30</td></tr><tr><td align="left" rowspan="4">30</td><td align="left">AKT3</td><td align="left">0.31</td><td align="left">0.078&#x02013;0.542</td><td align="left">0.09</td><td align="left">60</td><td align="left">30</td></tr><tr><td align="left">GSK-3&#x003b2;</td><td align="left">0.235</td><td align="left">0.067&#x02013;0.403</td><td align="left">0.02*</td><td align="left">90</td><td align="left">65</td></tr><tr><td align="left">MALAT-1</td><td align="left">
<bold>0.87</bold>
</td><td align="left">
<bold>0.74&#x02013;0.99</bold>
</td><td align="left">
<bold>0.001***</bold>
</td><td align="left">
<bold>90</bold>
</td><td align="left">
<bold>75</bold>
</td></tr><tr><td align="left">hsa-miR-16-5p</td><td align="left">1</td><td align="left">1&#x02013;1</td><td align="left">&#x0003c;&#x02009;0.0001****</td><td align="left">100</td><td align="left">100</td></tr><tr><td align="left" colspan="7">
<bold>sTBI vs. mTBI and modTBI</bold>
</td></tr><tr><td align="left">0</td><td align="left">AKT3</td><td align="left">0.49</td><td align="left">0.27&#x02013;0.72</td><td align="left">0.93</td><td align="left">60</td><td align="left">40</td></tr><tr><td align="left"/><td align="left">GSK-3&#x003b2;</td><td align="left">0.79</td><td align="left">0.624&#x02013;0.96</td><td align="left">0.009**</td><td align="left">80</td><td align="left">75</td></tr><tr><td align="left"/><td align="left">MALAT-1</td><td align="left">
<bold>0.85</bold>
</td><td align="left">
<bold>0.72&#x02013;0.99</bold>
</td><td align="left">
<bold>0.002**</bold>
</td><td align="left">
<bold>90</bold>
</td><td align="left">
<bold>70</bold>
</td></tr><tr><td align="left"/><td align="left">hsa-miR-16-5p</td><td align="left">0.31</td><td align="left">0.122&#x02013;0.498</td><td align="left">0.09</td><td align="left">60</td><td align="left">35</td></tr><tr><td align="left">5</td><td align="left">AKT3</td><td align="left">0.505</td><td align="left">0.29&#x02013;0.714</td><td align="left">0.96</td><td align="left">70</td><td align="left">50</td></tr><tr><td align="left"/><td align="left">GSK-3&#x003b2;</td><td align="left">0.6</td><td align="left">0.396&#x02013;0.804</td><td align="left">0.37</td><td align="left">70</td><td align="left">60</td></tr><tr><td align="left"/><td align="left">MALAT-1</td><td align="left">
<bold>0.985</bold>
</td><td align="left">
<bold>0.953-1</bold>
</td><td align="left">
<bold>&#x0003c;&#x02009;0.0001****</bold>
</td><td align="left">
<bold>90</bold>
</td><td align="left">
<bold>95</bold>
</td></tr><tr><td align="left"/><td align="left">hsa-miR-16-5p</td><td align="left">0.365</td><td align="left">0.167&#x02013;0.563</td><td align="left">0.23</td><td align="left">70</td><td align="left">25</td></tr><tr><td align="left">30</td><td align="left">AKT3</td><td align="left">0.45</td><td align="left">0.23&#x02013;0.668</td><td align="left">0.66</td><td align="left">60</td><td align="left">35</td></tr><tr><td align="left"/><td align="left">GSK-3&#x003b2;</td><td align="left">0.425</td><td align="left">0.13&#x02013;0.667</td><td align="left">0.509</td><td align="left">60</td><td align="left">25</td></tr><tr><td align="left"/><td align="left">MALAT-1</td><td align="left">
<bold>0.995</bold>
</td><td align="left">
<bold>0.97-1</bold>
</td><td align="left">
<bold>&#x0003c;&#x02009;0.0001****</bold>
</td><td align="left">
<bold>90</bold>
</td><td align="left">
<bold>95</bold>
</td></tr><tr><td align="left"/><td align="left">hsa-miR-16-5p</td><td align="left">0.455</td><td align="left">0.246&#x02013;0.664</td><td align="left">0.69</td><td align="left">60</td><td align="left">45</td></tr></tbody></table><table-wrap-foot><p>Bolded result indicates AUC at least 0.8 (at least &#x02018;good&#x02019; discrimination)</p><p>* Significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, ** significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, *** significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, **** significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001. ROC, Receiver&#x02013;operator curves</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec14"><title>Prognostic Performance of the MALAT-1, hsa-miR-16-5p, GSK-3&#x003b2;, and AKT3</title><p id="Par47">Regarding prognostic significance of these biomarkers, the outcomes were evaluated, with some patients experiencing recovery, some encountering complications, and others died. As shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>, MALAT-1 level significantly increased in patients who died in comparison to those who recovered. This increase was obvious when it was measured at 0, 5 or 30 days at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, 0.01, 0.001, respectively. The other biomarkers didn&#x02019;t show significant change according to the outcome of patients.</p><p id="Par48">
<fig id="Fig4"><label>Fig. 4</label><caption><p>The expression level of MALAT-1 according to patients&#x02019; outcome</p></caption><graphic xlink:href="11064_2024_4292_Fig4_HTML" id="d33e2061"/></fig>
</p></sec><sec id="Sec15"><title>Correlation Between Different Biomarkers and GCS</title><p id="Par49">Our analysis revealed opposite trends between gene expression and GCS scores. MALAT-1 levels showed a strong negative correlation (<italic>r</italic> = -0.62, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.01) with GCS, meaning higher MALAT-1 levels were associated with lower GCS scores (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A). Conversely, GSK-3&#x003b2; displayed a strong positive correlation (<italic>r</italic>&#x02009;=&#x02009;0.61, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) with GCS (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>B).</p><p id="Par50">
<fig id="Fig5"><label>Fig. 5</label><caption><p>Correlation between MALAT-1 (<bold>A</bold>) and GSK-3&#x003b2; (<bold>B</bold>) with GCS</p></caption><graphic xlink:href="11064_2024_4292_Fig5_HTML" id="d33e2101"/></fig>
</p></sec><sec id="Sec16"><title>Integrated Targets Prediction of MALAT-1 and hsa-miR-166-5a Target Genes and their Functional Enrichment Analysis and GO Annotation</title><p id="Par51">LncRNA was reported to sponge miRNAs which in turn regulates gene expression by attaching to a specific 3&#x02019;UTR of target genes and hindering their translation into proteins. hsa-miR-16-5 was one of the targeted miRNAs of the lncRNA MALAT-1. To understand the core function of hsa-miR-16-5a, its target genes were identified. A total of 361 overlapping genes were predicted using different prediction tools: TargetScan, RNAv22 and miRDB (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>).</p><p id="Par52">
<fig id="Fig6"><label>Fig. 6</label><caption><p>The lncRNA-miRNA-mRNA interaction network constructed with cytoscape. The network consists of the lncRNA MALAT-1 (red node), has-miR-16-5p (yellow), and their target genes (blue)</p></caption><graphic xlink:href="11064_2024_4292_Fig6_HTML" id="d33e2118"/></fig>
</p><p id="Par53">To get more insight into the cellular roles and patterns of regulation of hsa-miR-16-5p, the 361 overlapping predicted target genes were assessed by using the functional enrichment tool David and ShinyGO. The target genes were involved in various molecular functions (MFs) activities such as protein, metals, ATP, RNA, and cadherin binding, in addition to their involvement in ligase activity. When we analyzed the functions of these 361 target genes using Gene Ontology (GO) biological processes (BPs), we found they were primarily involved in several key processes, including transcription regulation, signal transduction, protein modification through ubiquitination (Ubl conjugation), and cell death pathways (apoptotic pathway). The molecules targeted by these circRNAs were mainly found in specific parts of the cells, the cytoplasm, nucleus, and plasma membrane. Moreover, the results showed that in the KEGG functional sets, mTOR, Rap1, calcium, Ras, Wnt signalling pathways were the common pathways enriched. Moreover, these target genes were mainly involved in Alzheimer&#x02019;s disease (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>).</p><p id="Par54">
<fig id="Fig7"><label>Fig. 7</label><caption><p>Gene ontology analysis for miR-16a-5p. Bar graphs show the enriched GO terms of molecular function (MF), cellular components (CC), and biological process (BP) arranged according to the number of genes (n) involved. Results are shown only for P value match of &#x0003c;&#x02009;0.001 and <italic>n</italic>&#x02009;&#x02265;&#x02009;5</p></caption><graphic xlink:href="11064_2024_4292_Fig7_HTML" id="d33e2137"/></fig>
</p></sec></sec><sec id="Sec17" sec-type="discussion"><title>Discussion</title><p id="Par55">Novel biomarkers for TBI are crucial for diagnosing, prognosing, and monitoring TBI patients, in addition to their significant relevance in forensic investigation due to their potential for fatalities, even when there are limited observable symptoms. Additionally, the timing of the injury can have significant relevance in forensic investigations as it can influence the stage of injury progression and healing processes [<xref ref-type="bibr" rid="CR8">8</xref>]. Moreover, the biomarkers associated with inflammation, tissue damage, and recovery pathways vary depending on the time elapsed since the injury occurred. Nonetheless, the complicated molecular mechanisms underlying traumatic processes and their effect on the brain remain largely unknown. The prospect of discovering novel biomarkers in the blood that can predict the severity and timing of an injury presents an exciting frontier in the field of forensic medicine.</p><p id="Par56">Recent systematic reviews have shown that a combination of tests involving the immediate identification of certain ncRNAs and mRNAs, which are either upregulated or downregulated, in various biological fluids, including CSF, blood or serum, can be effectively employed in clinical settings for nonstandard assessments and the prediction of TBI severity [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par57">In our current research, AKT3 was identified as an excellent diagnostic biomarker, showing a significant increase in all TBI cases but unable to distinguish between TBI severities. Although AKT3 levels are influenced by time and there was a notable decrease in AKT3 levels after 5 days, reaching their lowest point after 30 days in cases of modTBI and sTBI, but it can still be utilized as a biomarker for TBI patients at the initial assessment or after 5- or 30-days post injury. This finding aligns with prior research that reported the degradation of Akt3 within just one hour following a stroke event [<xref ref-type="bibr" rid="CR36">36</xref>]. Moreover, in the study of Zhao et al., (2012), AKT3 levels in rodents were increased after TBI, at 24&#x000a0;h post-injury then decreased after 3 days and reached their lowest point after 7 days [<xref ref-type="bibr" rid="CR37">37</xref>]. AKT3 was found to provide robust neuronal protection by enhancing mTOR activity [<xref ref-type="bibr" rid="CR38">38</xref>]. Moreover, AKT3 has been demonstrated to regulate the activity of GSK-3&#x003b2; through phosphorylation in response to the binding of growth factors via AKT3. This phosphorylation leads to the inactivation of GSK-3&#x003b2; and is believed to contribute to the anti-apoptotic properties associated with the activation of AKT3, thereby playing a protective role in TBI [<xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par58">The present study marks a pioneering attempt to investigate the expression level of GSK-3&#x003b2; in varying levels of severity of TBIs at three distinct time intervals. In our study, GSK-3&#x003b2; was identified as a diagnostic biomarker not only capable of distinguishing between TBI patients and the control group at different timing but also between patients with mTBI, modTBI, and sTBI. In addition, GSK-3&#x003b2; levels showed a further decrease after 5 and 30 days in mild TBI cases. Dash et al. (2011) [<xref ref-type="bibr" rid="CR39">39</xref>] reported that phosphorylation and inactivation of GSK-3&#x003b2; increases after injury and became statistically significant by day 3. Moreover, Shapira et al. [<xref ref-type="bibr" rid="CR40">40</xref>] reported the role of GSK-3 in early depressive behavior induced by mTBI. The AKT/GSK-3&#x003b2;/CRMP-2 signaling cascade is known to play a role in exacerbating neuronal apoptosis following early brain injury [<xref ref-type="bibr" rid="CR41">41</xref>].</p><p id="Par59">The total number of altered lncRNAs tends to correlate with the severity of brain injury which suggests their role in the pathological mechanisms associated with TBI [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. MALAT-1 was reported to control the key processes of angiogenesis following TBI by targeting the EZH2/NOTCH1 pathway [<xref ref-type="bibr" rid="CR20">20</xref>]. In this study, MALAT-1 showed a significant increase in its expression levels in sTBI patients compared to the control and those with mTBI or modTBI. Furthermore, this increase in expression level escalated over time, reaching its peak after 30 days. On the contrary, MALAT-1 was increased 6&#x000a0;h after TBI in rodents and then reached the lowest level at day seven [<xref ref-type="bibr" rid="CR20">20</xref>]. In our research, MALAT-1 emerged as a highly discriminative biomarker distinguishing between severe TBI, mild TBI, and moderate TBI at initial assessment, as well as at 5 and 30 days following the injury.</p><p id="Par60">Several miRNAs show potential as promising biomarkers that can unveil the primary and secondary molecular alterations following TBI [<xref ref-type="bibr" rid="CR44">44</xref>]. MiRNAs have a unique role in regulating protein expression and neural circuit creation [<xref ref-type="bibr" rid="CR15">15</xref>]. Damaged neurons appear to release miRNAs into the extracellular environment through microvesicles [<xref ref-type="bibr" rid="CR45">45</xref>]. Our findings revealed a noteworthy increase in hsa-miR-16-5p levels in cases of all TBI patients in comparison to the healthy volunteer group and therefore can be used as a good biomarker for diagnosis at initial assessment, as well as at 5 and 30 days following the injury. Interestingly, people with mTBI had higher levels of hsa-miR-16-5p compared to those with modTBI or sTBI and its level increased after 30 days. Previously, hsa-miR-16-5p was found to increase in mTBI to sTBI cases [<xref ref-type="bibr" rid="CR44">44</xref>]. This observation aligns with the conclusions drawn by Redell et al. [<xref ref-type="bibr" rid="CR46">46</xref>] who reported the elevation of miR-16 levels within the first day in patients with mTBI, while those with sTBI had the lowest levels.</p><p id="Par61">The GCS score has been recognized as a reliable indicator of injury severity and the evolution of brain damage [<xref ref-type="bibr" rid="CR47">47</xref>]. Nevertheless, recent studies have highlighted its subjectivity and vulnerability to complex clinical situations like sedation or shock [<xref ref-type="bibr" rid="CR48">48</xref>]. Consequently, the quest for reliable biomarkers that offer objective and quantifiable measures for assessing injuries and predicting outcomes is crucial. Our results proved by ROC curve analysis that hsa-miR-16-5p, AKT3, and GSK-3&#x003b2; can be a reliable indicator for diagnosis. Moreover, the fact that the expression level of different biomarkers changed at other times makes them helpful in evaluating the period after post-trauma. They also can be used for evaluation of prognosis, follow-up, and detection of severity of TBI. It is noteworthy that these biomarkers exhibited substantial alterations across the three groups and demonstrated the ability to differentiate between levels of severity. In contrast to CT scans that revealed changes within the three groups and were unable to distinguish between the varying levels of severity. Moreover, the current results proved a significant correlation between MALAT-1, GSK-3&#x003b2; and GCS. Previously, the lncRNA GAS5 was negatively correlated with GCS [<xref ref-type="bibr" rid="CR49">49</xref>].</p><p id="Par62">Bioinformatics was used to prove the indulgence of MALAT-1/hsa-miR-16-5p/AKT3/GSK-3&#x003b2; in the pathogenesis of TBI and get more insight into the cellular roles and patterns of regulation. lncRNA-miRNA-mRNA interaction network was constructed. hsa-miR-16-5p target genes were investigated. They were involved in cadherin binding and Ubl conjugation. Previously, TIMP2 was reported to treat TBI by cadherin internalization in mice [<xref ref-type="bibr" rid="CR50">50</xref>]. Moreover, Studies suggest that zinc might help protect brain cells&#x02019; neurons from damage after a head injury by reducing a cellular process called ubiquitin conjugation [<xref ref-type="bibr" rid="CR51">51</xref>]. Our investigations also revealed the involvement of hsa-miR-16-5p&#x02019;s genes in apoptotic, mTOR, Rap1, calcium, Ras, and Wnt signaling pathways which contribute to the overall pathology of TBI [<xref ref-type="bibr" rid="CR52">52</xref>]. mTOR inhibition and activation of the Epac/Rap1 signaling pathway may improve recovery after TBI in mice models. These treatments showed significant improvement in both thinking and movement abilities [<xref ref-type="bibr" rid="CR53">53</xref>]. RAS plays an important role in TBI and may contribute to permanent brain damage after TBI [<xref ref-type="bibr" rid="CR54">54</xref>]. The Wnt pathway plays an important role in TBI, especially WNT3A which showed a positive effect in promoting neuronal regeneration in TBI [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. These results will potentially open a new avenue of therapeutic strategies for TBI.</p><p id="Par63">The small sample size was a limitation in our study because of the slow enrollment of eligible patients during the research period. Nevertheless, the study leaned more towards being exploratory rather than confirmatory, yielding some notable outcomes. Consequently, we anticipate that a study with a larger sample size will validate and broaden our discoveries. Moreover, the prognostic and follow-up utility of these biomarkers should be further investigated.</p></sec><sec id="Sec18" sec-type="conclusion"><title>Conclusion</title><p id="Par64">In conclusion, this study explored that AKT3, GSK-3&#x003b2;, and hsa-miR-16a-5p had good diagnostic value in TBI patients at initial assessment, as well as at 5 and 30 days following the injury. Moreover, MALAT-1 had good diagnostic value in sTBI compared to mTBI and modTBI patients, and its prognostic value extends to 30 days. GSK-3&#x003b2; was an excellent biomarker for detecting mTBI. MALAT-1 showed a significant negative correlation with GCS. In contrast, GSK-3&#x003b2; showed a significant positive correlation with GCS. Owing to the preliminary study design, our findings still need further validation with larger sample size.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Yasmin Kamal Abd Rabou and Sally A. Fahim contributed equally to this work.</p></fn></fn-group><ack><title>Acknowledgements</title><p>NA.</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>Y.K.A.R: practical work, prepared the original draft; A.A.Z: conceptualization, revision; S.A.F: bioinformatics and statistical analysis, writing and final revision; M.A: practical work and methodology; A.E.F: clinical samples and data collection; N.N.F: reviewed the manuscript. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Faculty of Medicine, Cairo University.</p><p>Open access funding provided by The Science, Technology &#x00026; Innovation Funding Authority (STDF) in cooperation with The Egyptian Knowledge Bank (EKB).</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing Interests</title><p id="Par65">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Alam A et al (2020) Cellular infiltration in traumatic brain injury. <italic>Journal of neuroinflammation 2020 17:1</italic> 17, 1&#x02013;17</mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Alkhaibary A et al (2021) Traumatic Brain Injury: A Perspective on the Silent Epidemic. <italic>Cureus</italic> 13</mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>B</given-names></name><name><surname>Anderson</surname><given-names>DB</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name></person-group><article-title>Original research: global, regional and national burden of traumatic brain injury and spinal cord injury, 1990&#x02013;2019: a systematic analysis for the global burden of Disease Study 2019</article-title><source>BMJ Open</source><year>2023</year><volume>13</volume><fpage>75049</fpage></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Guan B, Anderson DB, Chen L, Feng S, Zhou H (2023) Original research: global, regional and national burden of traumatic brain injury and spinal cord injury, 1990&#x02013;2019: a systematic analysis for the global burden of Disease Study 2019. BMJ Open 13:75049</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Abio A et al (2021) Changes in Mortality related to traumatic brain injuries in the Seychelles from 1989 to 2018. Front Neurol 12</mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Schweitzer AD, Niogi SN, Whitlow CT, Tsiouris AJ (2019) Traumatic Brain Injury: imaging patterns and complications. 39(1571&#x02013;1595). 10.1148/rg.2019190076</mixed-citation></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Dadas</surname><given-names>A</given-names></name><name><surname>Washington</surname><given-names>J</given-names></name><name><surname>Diaz-Arrastia</surname><given-names>R</given-names></name><name><surname>Janigro</surname><given-names>D</given-names></name></person-group><article-title>Biomarkers in traumatic brain injury (TBI): a review</article-title><source>Neuropsychiatr Dis Treat</source><year>2018</year><volume>14</volume><fpage>2989</fpage><pub-id pub-id-type="pmid">30510421</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Dadas A, Washington J, Diaz-Arrastia R, Janigro D (2018) Biomarkers in traumatic brain injury (TBI): a review. Neuropsychiatr Dis Treat 14:2989<pub-id pub-id-type="pmid">30510421</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Mckee</surname><given-names>AC</given-names></name><name><surname>Daneshvar</surname><given-names>DH</given-names></name></person-group><article-title>The neuropathology of traumatic brain injury</article-title><source>Handb Clin Neurol</source><year>2015</year><volume>127</volume><fpage>45</fpage><pub-id pub-id-type="pmid">25702209</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Mckee AC, Daneshvar DH (2015) The neuropathology of traumatic brain injury. Handb Clin Neurol 127:45<pub-id pub-id-type="pmid">25702209</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Aromatario</surname><given-names>M</given-names></name><etal/></person-group><article-title>Traumatic epidural and subdural hematoma: Epidemiology, Outcome, and dating</article-title><source>Med (Kaunas)</source><year>2021</year><volume>57</volume><fpage>1</fpage><lpage>16</lpage></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Aromatario M et al (2021) Traumatic epidural and subdural hematoma: Epidemiology, Outcome, and dating. Med (Kaunas) 57:1&#x02013;16</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Cao</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zheng</surname><given-names>P</given-names></name></person-group><article-title>Expression profiles of long non-coding RNA and Messenger RNA in human traumatic brain Injury</article-title><source>Mol Ther Nucleic Acids</source><year>2020</year><volume>22</volume><fpage>99</fpage><pub-id pub-id-type="pmid">32919233</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Ren D, Chen W, Cao K, Wang Z, Zheng P (2020) Expression profiles of long non-coding RNA and Messenger RNA in human traumatic brain Injury. Mol Ther Nucleic Acids 22:99<pub-id pub-id-type="pmid">32919233</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The role of long noncoding RNA in traumatic brain injury</article-title><source>Neuropsychiatr Dis Treat</source><year>2019</year><volume>15</volume><fpage>1671</fpage><pub-id pub-id-type="pmid">31303755</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Li Z et al (2019) The role of long noncoding RNA in traumatic brain injury. Neuropsychiatr Dis Treat 15:1671<pub-id pub-id-type="pmid">31303755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>W</given-names></name><name><surname>Jiao</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Shao</surname><given-names>J</given-names></name></person-group><article-title>MicroRNA-21 in the Pathogenesis of Traumatic Brain Injury</article-title><source>Neurochem Res</source><year>2018</year><volume>43</volume><fpage>1863</fpage><lpage>1868</lpage><pub-id pub-id-type="pmid">30066160</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Ji W, Jiao J, Cheng C, Shao J (2018) MicroRNA-21 in the Pathogenesis of Traumatic Brain Injury. Neurochem Res 43:1863&#x02013;1868<pub-id pub-id-type="pmid">30066160</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Increased mir-124-3p in microglial exosomes following traumatic brain injury inhibits neuronal inflammation and contributes to neurite outgrowth via their transfer into neurons</article-title><source>FASEB J</source><year>2018</year><volume>32</volume><fpage>512</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">28935818</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Huang S et al (2018) Increased mir-124-3p in microglial exosomes following traumatic brain injury inhibits neuronal inflammation and contributes to neurite outgrowth via their transfer into neurons. FASEB J 32:512&#x02013;528<pub-id pub-id-type="pmid">28935818</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Beylerli</surname><given-names>O</given-names></name><etal/></person-group><article-title>Role of exosomal ncRNAs in traumatic brain injury</article-title><source>Noncoding RNA Res</source><year>2023</year><volume>8</volume><fpage>686</fpage><pub-id pub-id-type="pmid">37860267</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Beylerli O et al (2023) Role of exosomal ncRNAs in traumatic brain injury. Noncoding RNA Res 8:686<pub-id pub-id-type="pmid">37860267</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>RT</given-names></name><etal/></person-group><article-title>Circular ribonucleic acid expression alteration in Exosomes from the Brain Extracellular Space after Traumatic Brain Injury in mice</article-title><source>J Neurotrauma</source><year>2018</year><volume>35</volume><fpage>2056</fpage><lpage>2066</lpage><pub-id pub-id-type="pmid">29409384</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Zhao RT et al (2018) Circular ribonucleic acid expression alteration in Exosomes from the Brain Extracellular Space after Traumatic Brain Injury in mice. J Neurotrauma 35:2056&#x02013;2066<pub-id pub-id-type="pmid">29409384</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Connell</surname><given-names>GC</given-names></name><name><surname>Smothers</surname><given-names>CG</given-names></name><name><surname>Winkelman</surname><given-names>C</given-names></name></person-group><article-title>Bioinformatic analysis of brain-specific miRNAs for identification of candidate traumatic brain injury blood biomarkers</article-title><source>Brain Inj</source><year>2020</year><volume>34</volume><fpage>965</fpage><lpage>974</lpage><pub-id pub-id-type="pmid">32497449</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">O&#x02019;Connell GC, Smothers CG, Winkelman C (2020) Bioinformatic analysis of brain-specific miRNAs for identification of candidate traumatic brain injury blood biomarkers. Brain Inj 34:965&#x02013;974<pub-id pub-id-type="pmid">32497449</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Using bioinformatics technology to mine the expression of serum exosomal miRNA in patients with traumatic brain injury</article-title><source>Front Neurosci</source><year>2023</year><volume>17</volume><fpage>1145307</fpage><pub-id pub-id-type="pmid">37144089</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Huang X et al (2023) Using bioinformatics technology to mine the expression of serum exosomal miRNA in patients with traumatic brain injury. Front Neurosci 17:1145307<pub-id pub-id-type="pmid">37144089</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Brien</surname><given-names>J</given-names></name><name><surname>Hayder</surname><given-names>H</given-names></name><name><surname>Zayed</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name></person-group><article-title>Overview of microRNA biogenesis, mechanisms of actions, and circulation</article-title><source>Front Endocrinol (Lausanne)</source><year>2018</year><volume>9</volume><fpage>388354</fpage></element-citation><mixed-citation id="mc-CR17" publication-type="journal">O&#x02019;Brien J, Hayder H, Zayed Y, Peng C (2018) Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne) 9:388354</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Atif</surname><given-names>H</given-names></name><name><surname>Hicks</surname><given-names>SD</given-names></name></person-group><article-title>A review of MicroRNA biomarkers in traumatic brain Injury</article-title><source>J Exp Neurosci</source><year>2019</year><volume>13</volume><fpage>117906951983228</fpage></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Atif H, Hicks SD (2019) A review of MicroRNA biomarkers in traumatic brain Injury. J Exp Neurosci 13:117906951983228</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Downregulation of microRNA-16-5p accelerates fracture healing by promoting proliferation and inhibiting apoptosis of osteoblasts in patients with traumatic brain injury</article-title><source>Am J Transl Res</source><year>2019</year><volume>11</volume><fpage>4746</fpage><pub-id pub-id-type="pmid">31497196</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Sun Y et al (2019) Downregulation of microRNA-16-5p accelerates fracture healing by promoting proliferation and inhibiting apoptosis of osteoblasts in patients with traumatic brain injury. Am J Transl Res 11:4746<pub-id pub-id-type="pmid">31497196</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>N</given-names></name><etal/></person-group><article-title>Essential role of MALAT1 in reducing traumatic brain injury</article-title><source>Neural Regen Res</source><year>2022</year><volume>17</volume><fpage>1776</fpage><pub-id pub-id-type="pmid">35017438</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Wu N et al (2022) Essential role of MALAT1 in reducing traumatic brain injury. Neural Regen Res 17:1776<pub-id pub-id-type="pmid">35017438</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name></person-group><article-title>Long non-coding RNA in CNS injuries: a new target for therapeutic intervention</article-title><source>Mol Ther Nucleic Acids</source><year>2019</year><volume>17</volume><fpage>754</fpage><pub-id pub-id-type="pmid">31437654</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Zhang L, Wang H (2019) Long non-coding RNA in CNS injuries: a new target for therapeutic intervention. Mol Ther Nucleic Acids 17:754<pub-id pub-id-type="pmid">31437654</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>S</given-names></name><etal/></person-group><article-title>GSK3 inhibitors show benefits in an Alzheimer&#x02019;s disease (AD) model of neurodegeneration but adverse effects in control animals</article-title><source>Neurobiol Dis</source><year>2009</year><volume>33</volume><fpage>193</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">19038340</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Hu S et al (2009) GSK3 inhibitors show benefits in an Alzheimer&#x02019;s disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 33:193&#x02013;206<pub-id pub-id-type="pmid">19038340</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Farr</surname><given-names>SA</given-names></name><name><surname>Niehoff</surname><given-names>ML</given-names></name><name><surname>Kumar</surname><given-names>VB</given-names></name><name><surname>Roby</surname><given-names>DA</given-names></name><name><surname>Morley</surname><given-names>JE</given-names></name></person-group><article-title>Inhibition of glycogen synthase kinase 3&#x003b2; as a treatment for the Prevention of Cognitive deficits after a traumatic brain Injury</article-title><source>J Neurotrauma</source><year>2019</year><volume>36</volume><fpage>1869</fpage><lpage>1875</lpage><pub-id pub-id-type="pmid">30704365</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Farr SA, Niehoff ML, Kumar VB, Roby DA, Morley JE (2019) Inhibition of glycogen synthase kinase 3&#x003b2; as a treatment for the Prevention of Cognitive deficits after a traumatic brain Injury. J Neurotrauma 36:1869&#x02013;1875<pub-id pub-id-type="pmid">30704365</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Noshita</surname><given-names>N</given-names></name><name><surname>Lew&#x000e9;n</surname><given-names>A</given-names></name><name><surname>Sugawara</surname><given-names>T</given-names></name><name><surname>Chan</surname><given-names>PH</given-names></name></person-group><article-title>Akt phosphorylation and neuronal survival after traumatic brain Injury in mice</article-title><source>Neurobiol Dis</source><year>2002</year><volume>9</volume><fpage>294</fpage><lpage>304</lpage><pub-id pub-id-type="pmid">11950275</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Noshita N, Lew&#x000e9;n A, Sugawara T, Chan PH (2002) Akt phosphorylation and neuronal survival after traumatic brain Injury in mice. Neurobiol Dis 9:294&#x02013;304<pub-id pub-id-type="pmid">11950275</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>DuBois</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Akt3-Mediated Protection Against Inflammatory demyelinating disease</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><fpage>1738</fpage><pub-id pub-id-type="pmid">31404142</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">DuBois JC et al (2019) Akt3-Mediated Protection Against Inflammatory demyelinating disease. Front Immunol 10:1738<pub-id pub-id-type="pmid">31404142</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">McGeary SE et al (2019) The biochemical basis of microRNA targeting efficacy. Science 366</mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>miRDB: an online database for prediction of functional microRNA targets</article-title><source>Nucleic Acids Res</source><year>2020</year><volume>48</volume><fpage>D127</fpage><lpage>D131</lpage><pub-id pub-id-type="pmid">31504780</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Chen Y, Wang X (2020) miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res 48:D127&#x02013;D131<pub-id pub-id-type="pmid">31504780</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>KC</given-names></name><etal/></person-group><article-title>A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes</article-title><source>Cell</source><year>2006</year><volume>126</volume><fpage>1203</fpage><lpage>1217</lpage><pub-id pub-id-type="pmid">16990141</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Miranda KC et al (2006) A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126:1203&#x02013;1217<pub-id pub-id-type="pmid">16990141</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Dudekula</surname><given-names>DB</given-names></name><etal/></person-group><article-title>CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs</article-title><source>RNA Biol</source><year>2016</year><volume>13</volume><fpage>34</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">26669964</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Dudekula DB et al (2016) CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol 13:34&#x02013;42<pub-id pub-id-type="pmid">26669964</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cytoscape: a Software Environment for Integrated Models of Biomolecular Interaction Networks</article-title><source>Genome Res</source><year>2003</year><volume>13</volume><fpage>2498</fpage><pub-id pub-id-type="pmid">14597658</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Shannon P et al (2003) Cytoscape: a Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Res 13:2498<pub-id pub-id-type="pmid">14597658</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Sherman</surname><given-names>BT</given-names></name><etal/></person-group><article-title>DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)</article-title><source>Nucleic Acids Res</source><year>2022</year><volume>50</volume><fpage>W216</fpage><lpage>W221</lpage><pub-id pub-id-type="pmid">35325185</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Sherman BT et al (2022) DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res 50:W216&#x02013;W221<pub-id pub-id-type="pmid">35325185</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Bilgin</surname><given-names>S</given-names></name><name><surname>Guclu-Gunduz</surname><given-names>A</given-names></name><name><surname>Oruckaptan</surname><given-names>H</given-names></name><name><surname>Kose</surname><given-names>N</given-names></name><name><surname>Celik</surname><given-names>B</given-names></name></person-group><article-title>Gait and Glasgow Coma Scale scores can predict functional recovery in patients with traumatic brain injury</article-title><source>Neural Regen Res</source><year>2012</year><volume>7</volume><fpage>1978</fpage><pub-id pub-id-type="pmid">25624828</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Bilgin S, Guclu-Gunduz A, Oruckaptan H, Kose N, Celik B (2012) Gait and Glasgow Coma Scale scores can predict functional recovery in patients with traumatic brain injury. Neural Regen Res 7:1978<pub-id pub-id-type="pmid">25624828</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>YH</given-names></name></person-group><article-title>Biostatistics 103: qualitative data-tests of independence</article-title><source>Singap Med J</source><year>2003</year><volume>44</volume><fpage>498</fpage><lpage>503</lpage></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Chan YH (2003) Biostatistics 103: qualitative data-tests of independence. Singap Med J 44:498&#x02013;503</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>YH</given-names></name></person-group><article-title>Biostatistics104: Correlational Analysis</article-title><source>Singap Med J</source><year>2003</year><volume>44</volume><fpage>614</fpage><lpage>619</lpage></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Chan YH (2003) Biostatistics104: Correlational Analysis. Singap Med J 44:614&#x02013;619</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Hiskens MI, Mengistu TS, Li KM, Fenning AS (2022) Systematic review of the Diagnostic and Clinical Utility of salivary microRNAs in traumatic Brain Injury (TBI). Int J Mol Sci 23</mixed-citation></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>R</given-names></name><etal/></person-group><article-title>Akt isoforms differentially protect against stroke-induced neuronal injury by regulating mTOR activities</article-title><source>J Cereb Blood Flow Metabolism</source><year>2013</year><volume>33</volume><fpage>1875</fpage></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Xie R et al (2013) Akt isoforms differentially protect against stroke-induced neuronal injury by regulating mTOR activities. J Cereb Blood Flow Metabolism 33:1875</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S</given-names></name><etal/></person-group><article-title>Activation of Akt/GSK-3beta/beta-catenin signaling pathway is involved in survival of neurons after traumatic brain injury in rats</article-title><source>Neurol Res</source><year>2012</year><volume>34</volume><fpage>400</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">22643085</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Zhao S et al (2012) Activation of Akt/GSK-3beta/beta-catenin signaling pathway is involved in survival of neurons after traumatic brain injury in rats. Neurol Res 34:400&#x02013;407<pub-id pub-id-type="pmid">22643085</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Xu F, Na L, Li Y, Chen L (2020) Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours. Cell Biosci 10</mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Dash PK et al (2011) Involvement of the glycogen synthase kinase-3 signaling pathway in TBI pathology and neurocognitive outcome. PLoS ONE 6</mixed-citation></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Shapira</surname><given-names>M</given-names></name><etal/></person-group><article-title>Role of glycogen synthase kinase-3beta in early depressive behavior induced by mild traumatic brain injury</article-title><source>Mol Cell Neurosci</source><year>2007</year><volume>34</volume><fpage>571</fpage><lpage>577</lpage><pub-id pub-id-type="pmid">17289399</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Shapira M et al (2007) Role of glycogen synthase kinase-3beta in early depressive behavior induced by mild traumatic brain injury. Mol Cell Neurosci 34:571&#x02013;577<pub-id pub-id-type="pmid">17289399</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><etal/></person-group><article-title>PTEN and AKT/GSK-3&#x003b2;/CRMP-2 signaling pathway are involved in neuronal apoptosis and axonal injury in early brain injury after SAH in rats</article-title><source>Genes Dis</source><year>2022</year><volume>9</volume><fpage>252</fpage><pub-id pub-id-type="pmid">35005122</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Chen H et al (2022) PTEN and AKT/GSK-3&#x003b2;/CRMP-2 signaling pathway are involved in neuronal apoptosis and axonal injury in early brain injury after SAH in rats. Genes Dis 9:252<pub-id pub-id-type="pmid">35005122</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Significant changes in circular RNA in the mouse cerebral cortex around an injury site after traumatic brain injury</article-title><source>Exp Neurol</source><year>2019</year><volume>313</volume><fpage>37</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">30529438</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Chen Z et al (2019) Significant changes in circular RNA in the mouse cerebral cortex around an injury site after traumatic brain injury. Exp Neurol 313:37&#x02013;48<pub-id pub-id-type="pmid">30529438</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>J</given-names></name><etal/></person-group><article-title>Altered expression of long non-coding RNA and mRNA in mouse cortex after traumatic brain injury</article-title><source>Brain Res</source><year>2016</year><volume>1646</volume><fpage>589</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">27380725</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Zhong J et al (2016) Altered expression of long non-coding RNA and mRNA in mouse cortex after traumatic brain injury. Brain Res 1646:589&#x02013;600<pub-id pub-id-type="pmid">27380725</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="other">Bhomia M, Balakathiresan NS, Wang KK, Papa L, Maheshwari RK (2016) A Panel of Serum MiRNA Biomarkers for the Diagnosis of Severe to Mild Traumatic Brain Injury in Humans. <italic>Scientific Reports 2016 6:1</italic> 6, 1&#x02013;12</mixed-citation></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Pinchi</surname><given-names>E</given-names></name><etal/></person-group><article-title>MicroRNAs: the New Challenge for traumatic brain Injury diagnosis</article-title><source>Curr Neuropharmacol</source><year>2020</year><volume>18</volume><fpage>319</fpage><pub-id pub-id-type="pmid">31729300</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Pinchi E et al (2020) MicroRNAs: the New Challenge for traumatic brain Injury diagnosis. Curr Neuropharmacol 18:319<pub-id pub-id-type="pmid">31729300</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Redell</surname><given-names>JB</given-names></name><name><surname>Moore</surname><given-names>AN</given-names></name><name><surname>Ward</surname><given-names>NH</given-names></name><name><surname>Hergenroeder</surname><given-names>GW</given-names></name><name><surname>Dash</surname><given-names>PK</given-names></name></person-group><article-title>Human traumatic brain Injury alters plasma microRNA levels</article-title><source>J Neurotrauma</source><year>2010</year><volume>27</volume><fpage>2147</fpage><pub-id pub-id-type="pmid">20883153</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Redell JB, Moore AN, Ward NH, Hergenroeder GW, Dash PK (2010) Human traumatic brain Injury alters plasma microRNA levels. J Neurotrauma 27:2147<pub-id pub-id-type="pmid">20883153</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Teasdale</surname><given-names>G</given-names></name><etal/></person-group><article-title>The Glasgow Coma Scale at 40 years: standing the test of time</article-title><source>Lancet Neurol</source><year>2014</year><volume>13</volume><fpage>844</fpage><lpage>854</lpage><pub-id pub-id-type="pmid">25030516</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Teasdale G et al (2014) The Glasgow Coma Scale at 40 years: standing the test of time. Lancet Neurol 13:844&#x02013;854<pub-id pub-id-type="pmid">25030516</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Laureys</surname><given-names>S</given-names></name><name><surname>Bodart</surname><given-names>O</given-names></name><name><surname>Gosseries</surname><given-names>O</given-names></name></person-group><article-title>The Glasgow Coma Scale: time for critical reappraisal?</article-title><source>Lancet Neurol</source><year>2014</year><volume>13</volume><fpage>755</fpage><lpage>757</lpage><pub-id pub-id-type="pmid">25030507</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Laureys S, Bodart O, Gosseries O (2014) The Glasgow Coma Scale: time for critical reappraisal? Lancet Neurol 13:755&#x02013;757<pub-id pub-id-type="pmid">25030507</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="other">Lei J et al (2022) Levels of lncRNA GAS5 in plasma of patients with severe traumatic brain Injury: correlation with systemic inflammation and early outcome. J Clin Med 11</mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Tang J et al (2023) TIMP2 ameliorates blood-brain barrier disruption in traumatic brain injury by inhibiting src-dependent VE-cadherin internalization. J Clin Invest 134</mixed-citation></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>KJ</given-names></name><etal/></person-group><article-title>Zinc as mediator of ubiquitin conjugation following traumatic brain injury</article-title><source>Brain Res</source><year>2013</year><volume>1506</volume><fpage>132</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">23419896</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Sun KJ et al (2013) Zinc as mediator of ubiquitin conjugation following traumatic brain injury. Brain Res 1506:132&#x02013;141<pub-id pub-id-type="pmid">23419896</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Raghupathi</surname><given-names>R</given-names></name><name><surname>Graham</surname><given-names>DI</given-names></name><name><surname>McIntosh</surname><given-names>T</given-names></name></person-group><article-title>K. Apoptosis after traumatic brain injury</article-title><source>J Neurotrauma</source><year>2000</year><volume>17</volume><fpage>927</fpage><lpage>938</lpage><pub-id pub-id-type="pmid">11063058</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Raghupathi R, Graham DI, McIntosh T (2000) K. Apoptosis after traumatic brain injury. J Neurotrauma 17:927&#x02013;938<pub-id pub-id-type="pmid">11063058</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Sun X et al (2023) Activation of the Epac/Rap1 signaling pathway alleviates blood-brain barrier disruption and brain damage following cerebral ischemia/reperfusion injury. Int Immunopharmacol 117</mixed-citation></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Vadhan</surname><given-names>JD</given-names></name><name><surname>Speth</surname><given-names>RC</given-names></name></person-group><article-title>The role of the brain renin-angiotensin system (RAS) in mild traumatic brain injury (TBI)</article-title><source>Pharmacol Ther</source><year>2021</year><volume>218</volume><fpage>107684</fpage><pub-id pub-id-type="pmid">32956721</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Vadhan JD, Speth RC (2021) The role of the brain renin-angiotensin system (RAS) in mild traumatic brain injury (TBI). Pharmacol Ther 218:107684<pub-id pub-id-type="pmid">32956721</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Chang CY et al (2020) WNT3A promotes neuronal regeneration upon traumatic brain Injury. Int J Mol Sci 21</mixed-citation></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other">Menet R, Lecordier S, ElAli A (2020) Wnt pathway: an emerging player in vascular and traumatic mediated brain injuries. Front Physiol 11</mixed-citation></ref></ref-list></back></article>